Welcome to our dedicated page for Omnicell news (Ticker: OMCL), a resource for investors and traders seeking the latest updates and insights on Omnicell stock.
Omnicell Inc. (OMCL) is a pioneering company that has been enhancing efficiencies in healthcare since 1992. As a leading supplier of comprehensive automation and business analytics software, Omnicell focuses on patient-centric medication and supply management across the entire healthcare continuum. This includes acute care hospital settings, post-acute skilled nursing and long-term care facilities, as well as home care settings.
Omnicell's automated hardware/software systems for medication dispensing provide seamless solutions from the point of hospital entry to the central pharmacy, nursing units, operating rooms, and patient bedsides. Their supply management systems are designed to promote cost control, ensure charge capture for payer reimbursement, and facilitate efficient inventory management and reordering.
Omnicell's range of products includes high-security, closed-cabinet systems, open-shelf systems, and combination systems that are used in nursing units, cath labs, and operating rooms. These solutions empower pharmacists and nurses to concentrate on patient care rather than administrative tasks, driving improved clinical, operational, and financial outcomes across diverse care settings. With over 3,200 customers worldwide, Omnicell continues to be a trusted partner in the healthcare sector.
In recent years, Omnicell has made significant strides in advancing their technology and expanding their service offerings. Their commitment to innovation is evident in the development of new products and partnerships that aim to further streamline medication management processes. Financially, the company generates the majority of its revenue in the United States, reflecting a strong market presence and consistent performance.
Omnicell (NASDAQ:OMCL) reported strong Q4 2024 financial results, with total revenues of $307 million, up 19% from Q4 2023. However, full-year 2024 revenues decreased 3% to $1.112 billion compared to 2023.
The company achieved GAAP net income of $16 million ($0.34 per diluted share) in Q4 2024, compared to a loss of $14 million in Q4 2023. Full-year 2024 GAAP net income was $13 million ($0.27 per diluted share).
Total bookings for 2024 reached $923 million, an 8% increase from 2023, driven by XT Series upgrades. The company's balance sheet showed $369 million in cash and cash equivalents, with total debt of $341 million. Omnicell issued $172.5 million in convertible senior notes and provided 2025 guidance projecting total revenues between $1.105-1.155 billion.
Omnicell (Nasdaq:OMCL), a company focused on transforming pharmacy and nursing care delivery models, has announced it will release its fourth quarter and full year 2024 financial results before market open on Thursday, February 6, 2025.
The company will host a conference call and webcast to discuss these results at 8:30 a.m. ET on the same day. Interested parties can join via phone using the numbers (800) 715-9871 (U.S.) or (646) 307-1963 (international) with Conference ID 2515873. A live and archived webcast will be available through Omnicell's Investor Relations website.
Omnicell (OMCL), a company focused on pharmacy care delivery transformation, has announced its upcoming presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Wednesday, January 15, 2025, at 1:30 p.m. PT.
Interested parties can access both live and archived versions of the presentation through the company's investor relations website at their events and presentations page. This participation in one of healthcare industry's premier conferences demonstrates Omnicell's continued engagement with the investment community.
Omnicell (Nasdaq:OMCL) has announced OmniSphere, a next-generation, cloud native software workflow engine and data platform designed to integrate enterprise robotics and smart devices for medication management. The platform aims to provide state-of-the-art security, improved productivity through single-point access, and enterprise-wide medication inventory visibility.
The company also revealed that its XT Amplify program solutions, including MedChill and XTExtend, are OmniSphere-ready. Additionally, MedChill now integrates with Follett refrigerators for temperature-controlled medications. Omnicell has also developed new DSCSA interface options with TrackTraceRX and LSPedia for its Central Pharmacy Manager software.
Omnicell (Nasdaq: OMCL), a leading pharmacy care delivery model transformation company, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The presentation is scheduled for Tuesday, December 3, 2024, at 2:00 p.m. ET. Both live and archived versions of the presentation will be accessible to interested parties through Omnicell's investor relations website in the events and presentations section.
Omnicell has announced the pricing of $150 million of 1.00% Convertible Senior Notes due 2029. The notes will mature on December 1, 2029, with interest payable semiannually at 1.00% per annum. The initial conversion rate is 17.4662 shares per $1,000 principal amount, equivalent to $57.25 per share. The company expects net proceeds of approximately $144.2 million, which will be used to repurchase $400 million of existing 2025 notes and fund convertible note hedge transactions. The offering includes additional options for purchasers and various hedging arrangements to manage potential dilution.
Omnicell (NASDAQ: OMCL) announces plans to offer $150 million of Convertible Senior Notes due 2029 in a private placement to qualified institutional buyers. The company will grant initial purchasers an option for an additional $22.5 million. The notes will be senior unsecured obligations with semiannual interest payments. Omnicell plans to use the proceeds to fund convertible note hedge transactions and repurchase up to $400 million of its outstanding 0.25% Convertible Senior Notes due 2025.
Omnicell (NASDAQ:OMCL) reported Q3 2024 results with total revenues of $282 million, down 5% year-over-year. GAAP net income was $9 million ($0.19 per diluted share), compared to $6 million ($0.12 per diluted share) in Q3 2023. Non-GAAP net income reached $26 million ($0.56 per diluted share). The company raised its 2024 non-GAAP EBITDA and earnings guidance, expecting full-year revenues between $1.100-1.110 billion and non-GAAP earnings per share of $1.65-1.72.
Omnicell, Inc. (Nasdaq:OMCL), a leader in transforming the pharmacy care delivery model, has announced the release of its third quarter 2024 financial results. The results will be disclosed before market open on Wednesday, October 30, 2024. Following the release, the company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the financial outcomes.
Interested parties can participate in the live call by dialing (800) 715-9871 in the U.S. or (646) 307-1963 for international locations, using the Conference ID 6944646. Additionally, a link to the live and archived webcast will be available on the Investor Relations section of Omnicell's website.
Omnicell, Inc. (Nasdaq: OMCL) has appointed Nnamdi Njoku as Executive Vice President and Chief Operating Officer, effective October 7, 2024. In this newly created role, Njoku will lead the company's global operations, reporting to Randall Lipps, chairman, president, CEO, and founder of Omnicell.
Njoku brings approximately 25 years of experience in leading global operations at healthcare and medical technology organizations. He most recently served as President of Sports Medicine, Surgical, Upper Extremities and Restorative Therapies at Zimmer Biomet Holdings, Inc. Previously, he spent over 18 years at Medtronic plc, where he led a $2 billion Neuromodulation Operating Unit.
Omnicell, a leader in transforming the pharmacy care delivery model, expects Njoku's expertise to help scale pharmacy automation and drive multi-year innovation and excellence.
FAQ
What is the current stock price of Omnicell (OMCL)?
What is the market cap of Omnicell (OMCL)?
What is Omnicell Inc. known for?
When was Omnicell Inc. founded?
What types of healthcare settings does Omnicell serve?
How do Omnicell's products benefit healthcare providers?
What kinds of products does Omnicell offer?
How many customers does Omnicell have globally?
Where does Omnicell generate most of its revenue?
What recent achievements has Omnicell made?
How do Omnicell's supply management systems aid healthcare facilities?
What is the primary goal of Omnicell's products and services?
